A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).
Lim J, Wong A, Ow S, Eng L, Sundar R, Chan G, Yadav K, Heong V, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC). Journal Of Clinical Oncology 2019, 37: 1045-1045. DOI: 10.1200/jco.2019.37.15_suppl.1045.Peer-Reviewed Original ResearchDose-limiting toxicityDisease control ratePalmar-plantar erythrodysesthesiaDose reductionBreast cancerDose levelsMechanisms of endocrine resistanceRecommended phase 2 dosePhase 2 doseAdvanced/Metastatic Breast CancerHR+ breast cancerPhase Ib trialContinuous daily dosingSerial tumor biopsiesAnti-tumor activityStandard of careDose expansionG3 toxicityPrior CTPostmenopausal womenTumor biopsiesEndocrine resistanceDaily doseEstrogen receptorPreclinical studiesPhase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
Konstantinopoulos P, Liu J, Luo W, Krasner C, Ishizuka J, Gockley A, Buss M, Campos S, Stover E, Wright A, Growdon W, Curtis J, Peralta A, Basada P, Quinn R, Gray K, Penson R, Cannistra S, Fleming G, Matulonis U. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). Journal Of Clinical Oncology 2019, 37: 5502-5502. DOI: 10.1200/jco.2019.37.15_suppl.5502.Peer-Reviewed Original ResearchEndometrial cancerObjective responseMicrosatellite InstablePrior therapyPD-L1 negative tumorsProgression-free survival ratesPersistent endometrial cancerPhase 2 studyPD-L1 inhibitorsCo-primary endpointsG3 toxicityG5 toxicityMeasurable diseasePrimary endpointProtocol therapyUnacceptable toxicityPD-L1Negative tumorsImmunohistochemical lossIHC expressionEligibility criteriaMismatch repair proteinsSurvival rateMSS statusCohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply